New drug combo aims to rebuild bone in spinal cord injury patients
NCT ID NCT04232657
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a two-step drug treatment can improve bone density in people with long-term spinal cord injury who have bone loss. Participants receive either romosozumab (a bone-building drug) or a placebo for 12 months, followed by denosumab (a bone-strengthening drug) for another 12 months. The goal is to see if this approach can safely increase bone mass and reduce fracture risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
James J. Peters VA Medical Center, Bronx, NY
The Bronx, New York, 10468-3904, United States
-
Kessler Institute for Rehabilitation
West Orange, New Jersey, 07052, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can discarded bone reveal the secrets to stronger bones?
- Could a common diabetes drug weaken your bones?
- A tastier calcium chew might boost bone Health—But does it work?
- Exercise program aims to steady the stance of osteoporosis patients
- Can a Bone-Strengthening infusion given right after hip surgery prevent a second break?
- Can a single dose of zoledronic acid safely treat bone loss in dialysis patients?